FDA questions motavizumab safety

FDA questioned the risk-benefit profile of motavizumab in briefing documents posted ahead of Wednesday's Antiviral Drugs Advisory Committee meeting

Read the full 193 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE